Table 1.

Participant characteristics

	Discovery Cohorts N = 1316	Replication Cohorts N = 488	P-Value2
Sex [N (%)]			0.206
Female	951 (72.3)	372 (76.2)
Male	364 (27.7)	116 (23.8)
Other	1 (0.0)	--
Age1 [Mean Years (SD)]	51.3 (12.7)	47.3 (11.6)	<0.001
Race [N (%)]			<0.001
Black or African American	100 (7.6)	34 (7.0)
Native American, Alaska Native or Native Hawaiian	1 (0.1)	4 (0.8)
Asian	13 (1.0)	6 (1.2)
White	1199 (91.2)	402 (83.1)
Multi-Racial	0 (0.0)	11 (2.3)
Other	2 (0.2)	27 (5.6)
Ethnicity			<0.001
Hispanic or Latino	17 (1.3)	46 (9.5)
Not Hispanic or Latino	1303 (98.3)	438 (90.3)
Not Sure	6 (0.5)	1 (0.2)
Age of First Symptom Onset [Mean Years (SD)]	32.9 (10.7)	31.6 (11.2)	0.017
Age of MS Diagnosis [Mean Years (SD)]	36.9 (10.9)	34.9 (10.5)	0.001
Disease Duration3 [Mean Years (SD)]	14.5 (10.4)	12.4 (8.6)	<0.001
Type of DMT [N (%)]			<0.001
High Efficacy	408 (31.4)	140 (32.5)
Standard Efficacy	641 (49.3)	258 (59.9)
None	252 (19.4)	33 (7.7)
Duration on Current DMT [N (%)]			<0.001
<6 Months	150 (12.0)	27 (5.9)
6 Months to 5 Years	668 (53.4)	304 (66.5)
>5 Years	433 (34.6)	126 (27.6)
MSRS-R Composite Score [N, Median, (minimum, maximum)]	1272, 8.5 (0.0, 30.0)	488, 5.0 (0.0, 24.0)
PDDS [N, Median, (minimum, maximum)]	1258, 2.0 (0.0, 9.0)	482, 1.0 (0.0, 9.0)
Ambulation Assistance Required [N (%)]	394 (31.3%)	79 (16.4%)
No Ambulation Assistance Required [N (%)]	864 (68.7%)	403 (83.6%)
PROMIS Physical Function T-Score [N, Median, (minimum, maximum)]	667, 43.3 (15.4, 73.3)	434, 47.4 (15.4, 73.3)

Note:

^1.Participant’s age at the time of latest survey response for any of the three patient-reported outcomes.

^2.P-value calculated from paired t-test for continuous variables and chi-squared test for dichotomous or categorical variables.

^3.Disease duration is the time interval between age of the first MS-related symptom onset and age of the latest measured patient reported outcome.